Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

The biotech company reported second-quarter financial results on Friday ahead of market open, a day after announcing plans to ...

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

FDA-approved Spikevax has the same formulation as the Moderna COVID-19 vaccine that was previously authorized for emergency use in the U.S. 00:02 01:08 Author: Erin Jones, Ariane Datil Published ...

FDA-approved Spikevax has the same formulation as the Moderna COVID-19 vaccine that was previously authorized for emergency use in the U.S.

Spikevax has the same formulation as the Moderna COVID-19 vaccine that was authorized for emergency use (EUA) by the U.S. Food and Drug Administration (FDA) on Dec. 18, 2020, according to the FDA ...

Spikevax has the same formulation as the Moderna COVID-19 vaccine that was authorized for emergency use (EUA) by the U.S. Food and Drug Administration (FDA) on Dec. 18, 2020, according to the FDA ...